아시아태평양의 세포 및 유전자 치료 바이오 제조 시장(2022-2031년)

“The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market Expected to Reach $8.60 Billion by 2031.”

Introduction to Asia-Pacific (APAC) Cell and Gene Therapy Biomanufacturing Market

The Asia Pacific (APAC) Cell and Gene Therapy Biomanufacturing Market is expected to grow at a CAGR of 17.88% from $1.96 Billion in 2022 to $8.60 Billion in 2031 in the forecasted period of 2022-2031. APAC cell and gene therapy biomanufacturing industry is expected to grow due in part to the increasing number of authorized treatments and growing infrastructural requirements. Extensive biomanufacturing capabilities are also required due to the expanding target indications for gene and cell treatments.

Market Introduction

The industry for cell and gene therapy biomanufacturing in Asia-Pacific (APAC) is about to undergo a period of rapid expansion and change. This area is set to become a center for state-of-the-art biomanufacturing due to the rise of authorized medicines and the rising requirements for infrastructure. A significant need for large-scale biomanufacturing facilities in Asia-Pacific is being driven by the broadening range of target indications for gene and cell therapies. The APAC market for cell and gene therapy biomanufacturing is growing as a result of continued investment in this area by governments, pharmaceutical corporations, and academic organizations, which is helping to develop novel and perhaps life-saving medical therapies. In addition to seeing the creation of cutting-edge treatments, this area is essential to the world's biomanufacturing industry.

Market Segmentation:

Segmentation 1: by Product Type

• Consumables
• Equipment
• Software Solutions

Segmentation 2: by End User

• Life Science Companies
• Contract Research Organizations (CROs)
• Contract Manufacturing Organizations (CMOs)
• Cell Banks

Segmentation 3: by Country

• China
• Japan
• India
• South Korea
• Australia/New Zealand
• Rest-of-Asia-Pacific

Demand - Drivers and Limitations

The following are the drivers for the Asia-Pacific Cell and Gene Therapy Biomanufacturing Market:

• Expansion in Target Indications for Cell and Gene Therapies Creating a Demand for Large-Scale Biomanufacturing
• Entry of New Market Participants in Cell and Gene Therapies Driving the Demand for Biomanufacturing Facilities and Equipment
• Robust Clinical Pipeline Creating a Demand for Biomanufacturing Infrastructure

The market is expected to face some limitations as well due to the following challenges:

• High Set-Up Cost of Biomanufacturing Facilities

How can this report add value to an organization?

Workflow/Innovation Strategy: The APAC cell and gene therapy biomanufacturing market (by product type) has been segmented into consumables, equipment, and software solutions.

Growth/Marketing Strategy: Cell and gene therapy biomanufacturing is being used for upstream processing, harvesting, downstream processing, and other applications. Various companies are providing consumables and equipment aid in the manufacturing of various cell and gene therapies, which is also the key strategy for market players to excel in the current cell and gene therapy biomanufacturing market.

Competitive Strategy: Key players in the APAC cell and gene therapy biomanufacturing market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the APAC cell and gene therapy biomanufacturing market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

Table of Contents

1 Markets

• 1.1 Industry Outlook
  • 1.1.1 Market Overview and Ecosystem
  • 1.1.2 Key Trends
    • 1.1.2.1 Biomanufacturing 4.0
    • 1.1.2.2 Growing Single-Use Technology Market Penetration
    • 1.1.2.3 Shift from Open Processing to Closed Processing for Cell and Gene Therapy Biomanufacturing
    • 1.1.2.4 Leveraging Various Key Strategies to Diversify the Product Portfolio
  • 1.1.3 Opportunity Assessment
  • 1.1.4 Regulatory Framework
  • 1.1.5 Product Benchmarking
    • 1.1.5.1 Product Benchmarking (by Product Type)
    • 1.1.5.2 Comparative Analysis (by Equipment)
  • 1.1.6 Patent Analysis
    • 1.1.6.1 Patent Analysis (by Year)
    • 1.1.6.2 Patent Analysis (by Country)
    • 1.1.6.3 Awaited Technologies
  • 1.1.7 Business Model Analysis
  • 1.1.8 Pipeline Products
  • 1.1.9 Technology Adoption Matrix
  • 1.1.10 Funding Scenario
  • 1.1.11 Key Success Factors
• 1.2 Impact of COVID-19 on the Cell and Gene Therapy Biomanufacturing Market
  • 1.2.1 Recommendations to Manufacturers
• 1.3 Impact of Russo-Ukrainian War on Cell and Gene Therapy Biomanufacturing Market

2 Asia-Pacific

• 2.1 Asia-Pacific
  • 2.1.1 Key Findings and Opportunity Assessment
  • 2.1.2 Market Dynamics
    • 2.1.2.1 Impact Analysis
  • 2.1.3 Sizing and Forecast Analysis
    • 2.1.3.1 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
    • 2.1.3.2 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)
    • 2.1.3.3 Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Country)
      • 2.1.3.3.1 China
        • 2.1.3.3.1.1 China Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.1.2 China Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 2.1.3.3.2 Japan
        • 2.1.3.3.2.1 Japan Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.2.2 Japan Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 2.1.3.3.3 India
        • 2.1.3.3.3.1 India Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.3.2 India Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 2.1.3.3.4 South Korea
        • 2.1.3.3.4.1 South Korea Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.4.2 South Korea Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 2.1.3.3.5 Australia/New Zealand
        • 2.1.3.3.5.1 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.5.2 Australia/New Zealand Cell and Gene Therapy Biomanufacturing Market (by End User)
      • 2.1.3.3.6 Rest-of-Asia-Pacific
        • 2.1.3.3.6.1 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by Product Type)
        • 2.1.3.3.6.2 Rest-of-Asia-Pacific Cell and Gene Therapy Biomanufacturing Market (by End User)

3 Markets - Competitive Benchmarking and Company Profiles

• 3.1 Competitive Benchmarking
  • 3.1.1 Competitive Landscape
    • 3.1.1.1 Segmental Growth Share Matrix
      • 3.1.1.1.1 Growth Share Analysis (by Product Type)
      • 3.1.1.1.2 Growth Share Analysis (by Application)
    • 3.1.1.2 Competitive Index (Unmet Needs and Innovations)
    • 3.1.1.3 Company Position Analysis
    • 3.1.1.4 Key Strategies and Developments
      • 3.1.1.4.1 Funding Activities
      • 3.1.1.4.2 New Offerings
      • 3.1.1.4.3 Mergers and Acquisitions
      • 3.1.1.4.4 Partnerships, Alliances, and Business Expansions
      • 3.1.1.4.5 Key Development Analysis
• 3.2 Company Share Analysis
• 3.3 Company Profiles
  • 3.3.1 WuXi AppTec
    • 3.3.1.1 Company Overview
    • 3.3.1.2 Role of WuXi AppTec in the Cell and Gene Therapy Biomanufacturing Market
    • 3.3.1.3 Major Product: Key Specifications
    • 3.3.1.4 Customers and Competitions/Opportunities
      • 3.3.1.4.1 Key Competitors
    • 3.3.1.5 Analyst Perspective